Erasca Lands BMS Collaboration to Test ERAS-0015 With Navlimetostat in Pancreatic Cancer
ERAS has more than doubled off its 52-week low of $2.52.
Summary
Erasca signed a clinical trial collaboration and supply agreement with Bristol Myers Squibb to test its pan-RAS molecular glue ERAS-0015 alongside BMS's investigational PRMT5 inhibitor navlimetostat (BMS-986504) in MTAP-deleted pancreatic ductal adenocarcinoma. BMS will sponsor and run the Phase 1/2 trial; Erasca supplies the drug and keeps commercial rights to ERAS-0015, with the arrangement mutually non-exclusive. The rationale is mechanistic: nearly all MTAP-deleted pancreatic tumors carry co-occurring RAS mutations, so hitting RAS and PRMT5 together could deepen responses in a cancer with few good options. For a clinical-stage company, a Big Pharma partner sponsoring a trial validates the asset and offloads cost, though Erasca gives up no rights and books no upfront cash here. This builds on the August FDA Fast Track designation for ERAS-0015 in metastatic pancreatic cancer and follows the Q3 report showing a $51.3M net loss against $947.8M in cash and securities. BMS is the larger party but the news is marginal to its pipeline; Erasca is the primary beneficiary.
At the time of this announcement, ERAS was trading at $13.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $2.52 to $24.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.